Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 482,775 shares of the biopharmaceutical company’s stock after buying an additional 65,722 shares during the period. Los Angeles Capital Management LLC’s holdings in Gilead Sciences were worth $44,594,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in GILD. Amalgamated Bank increased its holdings in shares of Gilead Sciences by 0.5% in the fourth quarter. Amalgamated Bank now owns 246,038 shares of the biopharmaceutical company’s stock valued at $22,727,000 after purchasing an additional 1,242 shares during the period. Acorn Wealth Advisors LLC acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $217,000. Impax Asset Management Group plc increased its holdings in shares of Gilead Sciences by 126.9% in the fourth quarter. Impax Asset Management Group plc now owns 380,570 shares of the biopharmaceutical company’s stock valued at $35,153,000 after purchasing an additional 212,828 shares during the period. Edge Capital Group LLC acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $212,000. Finally, Rothschild Investment LLC increased its holdings in shares of Gilead Sciences by 7.3% in the fourth quarter. Rothschild Investment LLC now owns 4,463 shares of the biopharmaceutical company’s stock valued at $412,000 after purchasing an additional 303 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $17,597,559.49. This represents a 1.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 706,212 shares of company stock valued at $67,324,826 in the last quarter. Insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 1.0 %

Shares of GILD opened at $111.03 on Tuesday. The company has a market capitalization of $138.37 billion, a P/E ratio of 300.08, a P/E/G ratio of 0.71 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $111.99. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The stock has a 50-day moving average price of $95.79 and a 200 day moving average price of $89.08.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.85%. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on GILD shares. Robert W. Baird lifted their price target on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Finally, Oppenheimer boosted their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $102.08.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.